TYK2: An emerging therapeutic target in rheumatic disease
Nat Rev Rheumatol 2024;20(4):232–40 DOI 10.1038/s41584-024-01093-w
TYK2 inhibitors hold promise for the treatment of a distinct spectrum of autoimmune diseases, including SLE, and could potentially have a safety profile that differs from other JAK inhibitors.
This review by Morand, et al. details the current knowledge of TYK2 inhibitors and the relevant clinical trials for deucravacitinib, brepocitinib, and ropsacitinib. They also provide an overview of TYK2 signalling and potential indications for TYK2 blockade.
